These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) on Monday reported better-than-expected second-quarter sales results and raised its FY26 sales guidance above estimates. Jazz Pharmaceuticals reported quarterly earnings of $5.71 per share which missed the analyst consensus estimate of $6.18 per share. The company reported quart